Hormonal
Tirzepatide is associated with a higher incidence of gastrointestinal adverse events (nausea, vomiting, constipation, dyspepsia) compared to placebo, which increases with dose and leads to higher discontinuation rates, but does not increase the risk of serious adverse events.
Tirzepatide is more likely to cause stomach issues like nausea and vomiting than a placebo, and these side effects are more common at higher doses. This can lead to some people stopping the medication, but it does not increase the risk of serious health problems. Managing these side effects is key to staying on the treatment.
Adverse events were more frequent with tirzepatide than placebo (OR=1.34; p < 0.0001), largely driven by gastrointestinal symptoms, whereas serious adverse events did not differ. Discontinuations due to side effects increased at higher doses (OR=2.31; p < 0.0001).
Why this rating
Based on the same robust meta-analysis of 11 RCTs.
Source
Efficacy and safety of tirzepatide for weight loss in patients with obesity or type 2 diabetes: a systematic review and meta-analysis
Qiru Tian et al. · Frontiers in Endocrinology · 2025
DOI 10.3389/fendo.2025.1593134
More from this paper
- Tirzepatide induces significant, dose-dependent weight loss in patients with obesity or type 2 diabetes, with non-diabetic individuals experiencing greater absolute weight reduction than diabetic individuals at equivalent doses.Strong
- Tirzepatide increases the likelihood of achieving clinically meaningful weight loss thresholds (≥5%, ≥10%, ≥15%) in a dose-dependent manner, with 15 mg showing the highest odds ratios for all thresholds.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →